

# Rocío Gallego-Durán

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6918189/publications.pdf>

Version: 2024-02-01

36  
papers

1,275  
citations

430874

18  
h-index

377865

34  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2145  
citing authors

#	ARTICLE	IF	CITATIONS
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	12.1	113
2	Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 1410-1422.	3.9	14
3	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. <i>Scientific Reports</i> , 2022, 12, 3418.	3.3	19
4	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. <i>Journal of Gastroenterology</i> , 2022, 57, 357-371.	5.1	8
5	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. <i>Cancers</i> , 2022, 14, 192.	3.7	15
6	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
7	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1238-1247.	0.4	12
8	Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr <sup>-/-</sup> .Leiden mice without attenuation of steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 8250.	3.3	14
9	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	3.9	13
10	Management of NAFLD patients with advanced fibrosis. <i>Liver International</i> , 2021, 41, 95-104.	3.9	7
11	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	6.1	11
12	Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. <i>Journal of Hepatology</i> , 2021, 75, 924-934.	3.7	11
13	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
14	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
15	Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPICAR Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00203.	2.5	21
16	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	3.9	14
17	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59
18	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	2.5	3

#	ARTICLE	IF	CITATIONS
19	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- $\beta$ 1 dependent mechanisms. Scientific Reports, 2019, 9, 1439.	3.3	7
20	Impaired brain glymphatic flow in experimental hepatic encephalopathy. Journal of Hepatology, 2019, 70, 40-49.	3.7	55
21	A polymorphism in the Irisin-encoding gene (FND5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. Journal of Hepatology, 2019, 70, 494-500.	3.7	67
22	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. Revista Espanola De Enfermedades Digestivas, 2019, 111, 301-307.	0.3	2
23	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. Revista Espanola De Enfermedades Digestivas, 2019, 111, 270-274.	0.3	2
24	Natural Extracts Abolished Lipid Accumulation in Cells Harboring non-favourable PNPLA3 genotype. Annals of Hepatology, 2018, 17, 242-249.	1.5	10
25	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Alimentary Pharmacology and Therapeutics, 2018, 48, 1260-1270.	3.7	70
26	Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). International Journal of Molecular Sciences, 2018, 19, 911.	4.1	100
27	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 2018, 69, 1335-1348.	3.7	121
28	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS ONE, 2018, 13, e0191805.	2.5	33
29	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. Revista Espanola De Enfermedades Digestivas, 2018, 110, 427-433.	0.3	3
30	An extra virgin olive oil rich diet intervention ameliorates the nonalcoholic steatohepatitis induced by a high-fat Western-type diet in mice. Molecular Nutrition and Food Research, 2017, 61, 1600549.	3.3	37
31	Lactulose reduces bacterial <sc>DNA</sc> translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver International, 2017, 37, 212-223.	3.9	28
32	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1611-1618.	2.8	25
33	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 31421.	3.3	33
34	Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World Journal of Hepatology, 2015, 7, 2497.	2.0	38
35	Increased soluble <sc>CD</sc>36 is linked to advanced steatosis in nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2014, 44, 65-73.	3.4	49
36	Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. Revista Espanola De Enfermedades Digestivas, 2011, 103, 619-625.	0.3	3